Research suggests that silicon dioxide, the primary active component in food-grade diatomaceous earth, may have cholesterol-lowering properties, with one animal study finding reductions in total, VLDL, and LDL cholesterol of roughly 18–29% in rats fed a high-cholesterol diet, potentially through a mechanism involving bile acid binding and excretion. A separate laboratory study found that silicon dioxide powder was highly effective at removing lipids from human serum while leaving other serum components largely intact, though this was an in vitro delipidation experiment rather than a study of effects in living organisms. However, the available evidence consists entirely of animal studies and laboratory experiments — there are no human clinical trials — which significantly limits how confidently these findings can be applied to people. Adding further complexity, a 2015 mouse study found that orally ingested silicon dioxide nanoparticles altered cholesterol and triglyceride levels while also producing visible tissue damage in several organs, suggesting that particle size and formulation may meaningfully affect both efficacy and safety, and that the research picture remains incomplete and somewhat mixed.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| A food-grade silicon dioxide is hypocholesterolemic in the diet of cholestero... | Other | 1994 | Supports | 95 |
| Evaluation of four reagents for delipidation of serum. | Other | 1983 | Supports | 62 |
| In vivo toxicity of orally administrated silicon dioxide nanoparticles in hea... | Other | 2015 | Mixed | 58 |